[ CAS No. 548762-66-9 ] {[proInfo.proName]}

Name: 548762-66-9|(2S,5R)-tert-Butyl 2,5-dimethylpiperazine-1-carboxylate|97%
Brand: Ambeed
SKU: A539683
Price: 7.0 USD
Availability: InStock
Rating: 96 (30 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 548762-66-9 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 548762-66-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 548762-66-9 ]

SDS Specification

Alternatived Products of [ 548762-66-9 ]

Product Details of [ 548762-66-9 ]

CAS No. :	548762-66-9	MDL No. :	MFCD08686667
Formula :	C₁₁H₂₂N₂O₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	PGZCVLUQTJRRAA-BDAKNGLRSA-N
M.W :	214.30	Pubchem ID :	11745988
Synonyms :

Calculated chemistry of [ 548762-66-9 ]

Physicochemical Properties

Num. heavy atoms :	15
Num. arom. heavy atoms :	0
Fraction Csp3 :	0.91
Num. rotatable bonds :	3
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	68.12
TPSA :	41.57 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.67 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.92
Log Po/w (XLOGP3) :	1.32
Log Po/w (WLOGP) :	0.84
Log Po/w (MLOGP) :	1.15
Log Po/w (SILICOS-IT) :	0.69
Consensus Log Po/w :	1.38

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.8
Solubility :	3.38 mg/ml ; 0.0158 mol/l
Class :	Very soluble
Log S (Ali) :	-1.79
Solubility :	3.44 mg/ml ; 0.0161 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-1.6
Solubility :	5.42 mg/ml ; 0.0253 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	3.08

Safety of [ 548762-66-9 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 548762-66-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 548762-66-9 ]
Downstream synthetic route of [ 548762-66-9 ]

[ 548762-66-9 ] Synthesis Path-Upstream 1~7

1
[ 548762-65-8 ]
[ 548762-66-9 ]

Reference： [1] Journal of Organic Chemistry, 2003, vol. 68, # 10, p. 3976 - 3980

2
[ 1218941-14-0 ]
[ 548762-66-9 ]

Reference： [1] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 3, p. 828 - 831

3
[ 24424-99-5 ]
[ 548762-66-9 ]

Reference： [1] Journal of Organic Chemistry, 2003, vol. 68, # 10, p. 3976 - 3980

4
[ 155836-79-6 ]
[ 548762-66-9 ]

Reference： [1] Journal of Organic Chemistry, 2003, vol. 68, # 10, p. 3976 - 3980

5
[ 2815-34-1 ]
[ 548762-66-9 ]

Reference： [1] Journal of Organic Chemistry, 2003, vol. 68, # 10, p. 3976 - 3980

6
[ 548762-64-7 ]
[ 548762-66-9 ]

Reference： [1] Journal of Organic Chemistry, 2003, vol. 68, # 10, p. 3976 - 3980

7
[ 548762-58-9 ]
[ 548762-66-9 ]

Reference： [1] Journal of Organic Chemistry, 2003, vol. 68, # 10, p. 3976 - 3980

[ 548762-66-9 ] Synthesis Path-Downstream 1~88

1
[ 24424-99-5 ]
[ 548762-66-9 ]

Reference： [1]Journal of Organic Chemistry,2003,vol. 68,p. 3976 - 3980

2
[ 155836-79-6 ]
[ 548762-66-9 ]

Reference： [1]Journal of Organic Chemistry,2003,vol. 68,p. 3976 - 3980

3
(±)-trans-1-allyl-2,5-dimethylpiperazine [ No CAS ]
[ 548762-66-9 ]

Reference： [1]Journal of Organic Chemistry,2003,vol. 68,p. 3976 - 3980

4
[ 2815-34-1 ]
[ 548762-66-9 ]

Reference： [1]Journal of Organic Chemistry,2003,vol. 68,p. 3976 - 3980

5
[ 548762-66-9 ]
[ 155836-78-5 ]

Reference： [1]Journal of Organic Chemistry,2003,vol. 68,p. 3976 - 3980

6
[ 548762-66-9 ]
(2S,5R)-4-Allyl-2,5-dimethyl-piperazine-1-carboxylic acid naphthalen-1-ylamide [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2003,vol. 68,p. 3976 - 3980

7
[ 548762-64-7 ]
[ 548762-66-9 ]

Reference： [1]Journal of Organic Chemistry,2003,vol. 68,p. 3976 - 3980

8
[ 548762-58-9 ]
[ 548762-66-9 ]

Reference： [1]Journal of Organic Chemistry,2003,vol. 68,p. 3976 - 3980

9
(2R,5S)-1,4-Diallyl-2,5-dimethyl-piperazine; compound with GENERIC INORGANIC NEUTRAL COMPONENT [ No CAS ]
[ 548762-66-9 ]

Reference： [1]Journal of Organic Chemistry,2003,vol. 68,p. 3976 - 3980

10
[ 194032-16-1 ]
[ 548762-66-9 ]
trans-2,5-Dimethyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]piperazine dihydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 20 Trans-2,5-Dimethyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]piperazine dihydrochloride Using 0.34 g of <strong>[548762-66-9]trans-1-(tert-butoxycarbonyl)-2,5-dimethylpiperazine</strong> and 0.64 g of 5-chlorosulfonyl-4-methylisoquinoline, the procedure of Example 1 was otherwise repeated to provide 0.43 g of the objective compound (white crystals). m.p. 260-271 C. (decomp.) Elemental analysis (for C16 H21 N3 O2 S.2HCl) Calcd. (%): C, 48.98; H, 5.91; N, 10.71 Found (%): C, 48.79; H, 6.03; N, 10.57

Reference： [1]Patent: US6153608,2000,A

11
[ 431062-03-2 ]
[ 548762-66-9 ]
[ 1218941-15-1 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 828 - 831

12
[ 1218941-14-0 ]
[ 548762-66-9 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 828 - 831

14
(2S,5R)-tert-butyl 4-benzyl-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]
[ 548762-66-9 ]

Yield	Reaction Conditions	Operation in experiment
100%	With formic acid;palladium on carbon; In methanol; at 20℃;Inert atmosphere; Cooling with ice;	a-3-1-4) Preparation of (2S,5R)-tert-butyl 2,5-dim ethylpiperazine-1-carboxylate (2S,5R)-tert-butyl 4-benzyl-2,5-dimethylpiperazine-1-carboxylate (3.11 g, 10.2 mmol) was dissolved in methanol (19 mL), added palladium carbon (156 mg) under an argon atmosphere, and added formic acid (2.4 g, 51.1 mmol) under ice-cold conditions. The solution was reverted to room temperature, and stirred overnight. Then, the reaction solution was filtered through a pad of celite, and the filtrate was concentrated in vacuo. The obtained residue was added water and hexane, and extracted. An aqueous solution of sodium hydroxide was added to the aqueous layer, extracted with 2-methyltetrahydrofuran, dried over anhydrous sodium sulfate, concentrated in vacuo, and the title compound (2.21 g (yield >100%)) was obtained as a colorless oil. 1H-NMR (CDCl3) delta: 1.16 (3H, d, J=6.6 Hz), 1.21 (3H, d, J=6.6 Hz), 1.46 (9H, s), 2.48 (1H, d, J=12.8 Hz), 3.09-3.16 (1H, m), 3.18-3.24 (2H, m), 3.54 (1H, d, J=13.4 Hz), 4.15-4.30 (1H, m), 5.68 (1H, brs).

Reference： [1]Patent: US2010/280013,2010,A1 .Location in patent: Page/Page column 29

15
[ 1427-06-1 ]
[ 548762-66-9 ]
[ 1374891-78-7 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In dimethyl sulfoxide;	(a) (2S,5R)-4-(5-Methoxycarbonyl-pyridin-2-yl)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester A mixture of 6-fluoronicotinic acid methyl ester (200 mg, 1.29 mmol) and <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> was heated at 120 C. in DMSO (2.0 mL) with potassium carbonate (178 mg, 1.29 mmol) for 2 h. The reaction mixture was partitioned between ethyl acetate (20.0 mL) and water (5.0 mL). The organic layer was washed with water (2*5.0 mL), dried over sodium sulfate, filtered and concentrated to give the title intermediate as a yellowish oil.
	With potassium carbonate; In dimethyl sulfoxide; at 120℃; for 2h;Inert atmosphere;	(a) (2S,5R)-4-(5-Methoxycarbonyl-pyridin-2-yl)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester A mixture of 6-fluoronicotinic acid methyl ester (200 mg, 1.29 mmol) and <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> was heated at 120 C in DMSO (2.0 mL) with potassium carbonate (178 mg, 1.29 mmol) for 2 h. The reaction mixture was partitioned between ethyl acetate (20.0 mL) and water (5.0 mL). The organic layer was washed with water (2 x 5.0 mL), dried over sodium sulfate, filtered and concentrated to give the title intermediate as a yellowish oil.

Reference： [1]Patent: US2012/114600,2012,A1
[2]Patent: EP2635571,2015,B1 .Location in patent: Paragraph 0180

16
[ 548762-66-9 ]
[ 1374891-79-8 ]

Yield	Reaction Conditions	Operation in experiment
83%	With hydrogenchloride; N-ethyl-N,N-diisopropylamine; In cyclopentyl methyl ether; dimethyl sulfoxide;	(b) (2S,5R)-4-[5-(4-Bromo-3-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester The product of the previous step (3.86 g, 10.2 mmol) <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> (2.62 g, 12.2 mmol) and N,N-diisopropylethylamine (5.32 mL, 30.5) was dissolved in DMSO (12 mL). The reaction mixture heated at 120 C. for 3 h, diluted with EtOAc (100 mL), washed with water, and saturated NH4Cl, water, and brine. The reaction mixture was evaporated to about 40% volume and 3 M HCl in cyclopentyl methyl ether (4.24 mL, 12.7 mmol) was added slowly. Seeds from a previous run at smaller scale were added and the reaction mixture was stirred for 2 days and filtered to provide the HCl salt of the title intermediate (5.15 g, 83% yield). HPLC method C: Retention time=21.1 min

Reference： [1]Patent: US2012/114600,2012,A1
[2]Patent: EP2635571,2015,B1

17
[ 548762-66-9 ]
[ 1374892-23-5 ]

Yield	Reaction Conditions	Operation in experiment
57%	In dimethyl sulfoxide; N-ethyl-N,N-diisopropylamine;	The solid from the previous step was dissolved in a mixture of N,N-diisopropylethylamine (0.7 mL, 4 mmol) and DMSO (0.7 mL, 10 mmol) and <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> (590 mg, 2.7 mmol) was added and the reaction mixture heated at 120 C. overnight, concentrated by rotary evaporation, dissolved in a small amount of DCM and purified by silica gel chromatography (0-40% ethyl acetate:hexanes) to produce the title intermediate (613 mg, 57% yield) as a white solid. (m/z): [M+H]+ calcd for C24H27F4N4O4 591.12 found 591.4.

Reference： [1]Patent: US2012/114600,2012,A1

18
[ 4548-45-2 ]
[ 548762-66-9 ]
[ 1433280-13-7 ]

Yield	Reaction Conditions	Operation in experiment
81%	With potassium carbonate; In dimethyl sulfoxide; at 100℃;	(a) (2S,5R)-2,5-Dimethyl-4-(5-nitro-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester A mixture of 2-chloro-5-nitropyridine (1.0 g, 6.3 mmol), <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> (1.4 g, 6.3 mmol), and potassium carbonate (1.7 g, 13 mmol) was stirred in DMSO (5.0 mL, 70 mmol) at 100 C. overnight. The reaction mixture was filtered thru a silica gel pad, which was washed with EtOAc (200 mL). The filtrate was washed with water (2*10 mL), concentrated, and purified by silica gel chromatography (eluted with ethyl acetate/hexane=0 to 80%) to give the title intermediate (1.724 g, 81% yield) as a yellow solid.

Reference： [1]Patent: US2013/115194,2013,A1 .Location in patent: Paragraph 0340

19
[ 1374892-24-6 ]
[ 548762-66-9 ]
[ 1374892-23-5 ]

Yield	Reaction Conditions	Operation in experiment
57%	With N-ethyl-N,N-diisopropylamine; In dimethyl sulfoxide; at 120℃;	The solid from the previous step was dissolved in a mixture of N,N-diisopropylethylamine (0.7 mL, 4 mmol) and DMSO (0.7 mL, 10 mmol) and <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> (590 mg, 2.7 mmol) was added and the reaction mixture heated at 120 C. overnight, concentrated by rotary evaporation, dissolved in a small amount of DCM and purified by silica gel chromatography (0-40% ethyl acetate:hexanes) to produce the title intermediate (613 mg, 57% yield) as a white solid. (m/z): [M+H]+ calcd for C24H27F4N4O4 591.12. found 591.4.
57%	With N-ethyl-N,N-diisopropylamine; In dimethyl sulfoxide; at 120℃;Inert atmosphere;	The solid from the previous step was dissolved in a mixture of N,N-diisopropylethylamine (0.7 mL, 4 mmol) and DMSO (0.7 mL, 10 mmol) and <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> (590 mg, 2.7 mmol) was added and the reaction mixture heated at 120 C overnight, concentrated by rotary evaporation, dissolved in a small amount of DCM and purified by silica gel chromatography (0-40% ethyl acetate:hexanes) to produce the title intermediate (613 mg, 57 % yield) as a white solid. (m/z): [M+H]+ calcd for C24H27F4N4O4 591.12 found 591.4.

Reference： [1]Patent: US2013/115194,2013,A1 .Location in patent: Paragraph 0361
[2]Patent: EP2635571,2015,B1 .Location in patent: Paragraph 0222

20
[ 548762-66-9 ]
[ 1433280-12-6 ]

Reference： [1]Patent: US2013/115194,2013,A1

21
[ 548762-66-9 ]
((S)-1-{(2S,4S)-2-[4-(4'-{6-[(2R,5S)-4-((S)-2,2-dimethyl-cyclopropanecarbonyl)-2,5-dimethyl-piperazin-1-yl]-pyridin-3-ylcarbamoyl}-2'-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester di-trifluoroacetic acid salt [ No CAS ]

Reference： [1]Patent: US2013/115194,2013,A1

22
[ 548762-66-9 ]
C₄₅H₅₅F₃N₈O₇ [ No CAS ]

Reference： [1]Patent: US2013/115194,2013,A1

23
[ 548762-66-9 ]
{(S)-1-[(2S,4S)-2-(4-{4'-[6-((2R,5S)-2,5-dimethyl-piperazin-1-yl)-pyridin-3-ylcarbamoyl]-2'-trifluoromethoxy-biphenyl-4-yl}-1H-imidazol-2-yl)-4-methyl-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester tri-hydrochloride [ No CAS ]

Reference： [1]Patent: US2013/115194,2013,A1

24
[ 1374892-36-0 ]
[ 548762-66-9 ]
[ 1374892-35-9 ]

Yield	Reaction Conditions	Operation in experiment
29%	With N-ethyl-N,N-diisopropylamine; In dimethyl sulfoxide; at 120℃;	Half of the solid from the previous step was treated with N,N-diisopropylethylamine (0.5 mL, 3 mmol), DMSO (0.5 mL, 7 mmol) and <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> (273 mg, 1.27 mmol) and the reaction mixture was heated at 120 C. overnight, concentrated by rotary evaporation, dissolved in a small amount of DCM and purified by silica gel chromatography (0-50% ethyl acetate:hexanes) to produce the title intermediate (288 mg, 29% yield) as a yellow solid. (m/z): [M+H]+ calcd for C24H27F4N4O4 591.09; 593.09. found 593.2.
29%	With N-ethyl-N,N-diisopropylamine; In dimethyl sulfoxide; at 120℃;Inert atmosphere;	Half of the solid from the previous step was treated with N,N-diisopropylethylamine (0.5 mL, 3 mmol), DMSO (0.5 mL, 7 mmol) and <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> (273 mg, 1.27 mmol) and the reaction mixture was heated at 120 C overnight, concentrated by rotary evaporation, dissolved in a small amount of DCM and purified by silica gel chromatography (0-50% ethyl acetate:hexanes) to produce the title intermediate (288 mg, 29 % yield) as a yellow solid. (m/z): [M+H]+ calcd for C24H27F4N4O4 591.09, 593.09 found 593.2.

Reference： [1]Patent: US2013/115194,2013,A1 .Location in patent: Paragraph 0308
[2]Patent: EP2635571,2015,B1 .Location in patent: Paragraph 0237

25
[ 548762-66-9 ]
[ 1374892-68-8 ]

Reference： [1]Patent: EP2635571,2015,B1

26
[ 548762-66-9 ]
[ 1374883-22-3 ]

Reference： [1]Patent: EP2635571,2015,B1

27
[ 1374892-66-6 ]
[ 548762-66-9 ]
(2S,5R)-4-[5-(4-bromo-3-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester hydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
83%	With N-ethyl-N,N-diisopropylamine; In dimethyl sulfoxide; at 120℃; for 3h;	(b) (2S,5R)-4-[5-(4-Bromo-3-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester The product of the previous step (3.86 g, 10.2 mmol) <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> (2.62 g, 12.2 mmol) and N,N-diisopropylethylamine (5.32 mL, 30.5) was dissolved in DMSO (12 mL). The reaction mixture heated at 120 C. for 3 h, diluted with EtOAc (100 mL), washed with water, and saturated NH4Cl, water, and brine. The reaction mixture was evaporated to about 40% volume and 3 M HCl in cyclopentyl methyl ether (4.24 mL, 12.7 mmol) was added slowly. Seeds from a previous run at smaller scale were added and the reaction mixture was stirred for 2 days and filtered to provide the HCl salt of the title intermediate (5.15 g, 83% yield). Analytical HPLC: Retention time=21.1 min.

Reference： [1]Patent: US2013/295048,2013,A1 .Location in patent: Paragraph 0123; 0124

28
[ 350-46-9 ]
[ 548762-66-9 ]
(2S,5R)-tert-butyl 2,5-dimethyl-4-(4-nitrophenyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
72.4%	With potassium carbonate; In N,N-dimethyl-formamide; at 90℃; for 120h;	To a stirring suspension of 1-fluoro-4-nitrobenzene (0.60 g, 4.24 mmol) and potassium carbonate (2.34 g, 16.97 mmol) in anhydrous DMF (5 mL) was added (2S,5R)-tert- butyl 2,5-dimethylpiperazine-1-carboxylate (1 g, 4.67mmol) and the mixture heated at 90 C for 120 h. After cooling the mixture was partitioned between brine/water (1:1, 50 mL) and ethyl acetate (25 mL) . The aqueous layer was separated and extracted with ethyl acetate (3 x 25 mL) . The combined ethyl acetate fractions were washedwith brine/water (1:1, 4 x 12.5 mL), dried (anhydrous sodium sulfate), filtered and reduced in vacuo. The resulting residue was purified by silica gel chromatography (gradient 0-50% Ethyl Acetate in Cyclohexane) to afford the title compound (1.03 g, 72.4%) . ?H NMR (400 MHz, CDC13) : 3 8.12 (d, 2H), 6.77 (d,2H), 4.24-4.58 (m, 1H), 4.03-4.16 (m, 1H), 3.73-3.93 (m,1H), 3.31-3.49 (m, 3H), 1.49 (s, 9H), 1.24 (d, 3H), 1.18(d, 3H) . LCMS (Method C) : = 1.80 mm, m/z = 336 [M+H].

Reference： [1]Patent: WO2015/92431,2015,A1 .Location in patent: Page/Page column 138

29
[ 350-46-9 ]
[ 548762-66-9 ]
(2S,5R)-tert-butyl 2,5-dimethyl-4-(4-aminophenyl)piperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2015/92431,2015,A1

30
[ 369-34-6 ]
[ 548762-66-9 ]
(2S,5R)-tert-butyl 4-(2-fluoro-4-nitrophenyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
97%	With potassium carbonate; In N,N-dimethyl-formamide; at 100℃; for 192h;Inert atmosphere;	A suspension of 1,2-difluoro-4-nitrobenzene (371 mg,2.333 mmol), (2S,5R)-tert-butyl 2,5-dimethylpiperazine-1- carboxylate (500 mg, 2.333 mmol) and potassium carbonate(484 mg, 3.50 mmol) in anhydrous acetonitrile (3 mL) was heated to 100 C under a nitrogen atmosphere for 8 days. The reaction mixture was allowed to cool to room temperature, diluted with water (20 mL) and extracted into ethyl acetate (3 x 10 mL) . The combined organicphases were dried over Na2504, filtered and concentrated to dryness under reduced pressure. The residue was purified by Biotage chromatography (silica lOOg cartridge, cyclohexane:ethyl acetate, gradient elution from 95:5 to 60:40) to give the title compound as ayellow oil (800 mg, 97%) . ?H NMR (400 MHz, CDC13) : 0 7.97 (dd, 1H), 7.90 (dd, 1H), 6.84 (t, 1H), 4.42 (br s, 1H),

Reference： [1]Patent: WO2015/92431,2015,A1 .Location in patent: Page/Page column 193; 194

31
[ 369-34-6 ]
[ 548762-66-9 ]
(2S,5R)-tert-butyl 4-(2-fluoro-4-aminophenyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2015/92431,2015,A1

32
[ 548762-66-9 ]
(2S,5R)-4-(5-carboxy-pyridin-2-yl)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester tri-trifluoroacetate [ No CAS ]

Reference： [1]Patent: EP2635571,2015,B1

33
[ 548762-66-9 ]
C₃₉H₄₅F₃N₈O₅*(x)ClH [ No CAS ]

Reference： [1]Patent: EP2635571,2015,B1

34
[ 548762-66-9 ]
((S)-1-{(S)-2-[4-(4'-[6-((2R,5S)-2,5-dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2'-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester trihydrochloride [ No CAS ]

Reference： [1]Patent: EP2635571,2015,B1

35
[ 1374892-66-6 ]
[ 548762-66-9 ]
(2S,5R)-4-[5-(4-bromo-3-trifluoromethoxy-phenylcarbamoyl)pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester hydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
83%		(b) (2S,5R)-4-[5-(4-Bromo-3-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester The product of the previous step (3.86 g, 10.2 mmol) <strong>[548762-66-9](2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> (2.62 g, 12.2 mmol) and N,N-diisopropylethylamine (5.32 mL, 30.5) was dissolved in DMSO (12 mL). The reaction mixture heated at 120 C for 3 h, diluted with EtOAc (100 mL), washed with water, and saturated NH4Cl, water, and brine. The reaction mixture was evaporated to about 40% volume and 3 M HCl in cyclopentyl methyl ether (4.24 mL, 12.7 mmol) was added slowly. Seeds from a previous run at smaller scale were added and the reaction mixture was stirred for 2 days and filtered to provide the HCl salt of the title intermediate (5.15 g, 83 % yield). HPLC method C: Retention time = 21.1 min

Reference： [1]Patent: EP2635571,2015,B1 .Location in patent: Paragraph 0288; 0289

36
tert-butyl (2S,5R)-2,5-dimethyl-4-(2-nitrobenzenesulfonyl)piperazine-1-carboxylate [ No CAS ]
[ 548762-66-9 ]

Yield	Reaction Conditions	Operation in experiment
72%	With potassium carbonate; thiophenol; In acetonitrile; at 20 - 50℃; for 3h;	2,5-Dimethyl-4 - [(2-nitrophenyl) sulfonyl] piperazine- 1 -carboxylic acid (2S, 5R) -tert- butyl (3.21 g, 8.04 mmol) was dissolved in acetonitrile (47 mL) . Potassium carbonate (3.33 g, 24.1 mmol) and benzenethiol (1.33 g, 12.1 mmol) were added at room temperature, and the mixture was stirred at 50 C. for 3 hours. After confirming completion of the reaction, water was added to the reaction solution at 0 C. Thereafter, the reaction solution was extracted with ethyl acetate, the organic layer was washed with saturated brine, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified using silica gel column chromatography (chloroform / methanol) to obtain the title compound (1.23 g, yield 72%) as a yellow oily substance

Reference： [1]Patent: JP2015/48326,2015,A .Location in patent: Paragraph 0108; 0124

37
[ 548762-66-9 ]
(2R,5S)-1-{4-[2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropane-2-yl]-2-propylphenyl}-2,5-dimethylpiperazine [ No CAS ]

Reference： [1]Patent: JP2015/48326,2015,A

38
[ 548762-66-9 ]
1-[(2S,5R)-4-{4-[2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl]2-propylphenyl}-2,5-dimethylpiperazin-1-yl]-2-bromoethan-1-one [ No CAS ]

Reference： [1]Patent: JP2015/48326,2015,A

39
[ 548762-66-9 ]
(5S)-3-{2-[(2S,5R)-4-{4-[2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl]-2-propylphenyl}-2,5-dimethylpiperazin-1-yl]-2-oxoethyl}-5-methyl-5-[4-(propan-2-yloxy)phenyl]imidazolidine-2,4-dione [ No CAS ]

Reference： [1]Patent: JP2015/48326,2015,A

40
[ 548762-66-9 ]
(S)-3-(2-{(2S,5R)-4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-propylphenyl]-2,5-dimethylpiperazin-1-yl}-2-oxoethyl)-5-[4-(1-methylethoxy)phenyl]-5-methylimidazolidine-2,4-dione [ No CAS ]

Reference： [1]Patent: JP2015/48326,2015,A

41
4-[2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropane-2-yl]-1-bromo-2-propylbenzene [ No CAS ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-{4-[2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl]-2-propylphenyl}-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
38%	With tris-(dibenzylideneacetone)dipalladium(0); potassium tert-butoxide; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In toluene; at 60℃; for 13h;Inert atmosphere;	4- [2- (benzyloxy) -1,1,1,3,3,3-hexafluoropropane-2-yl] -1-bromo-2-propylbenzene (150 mg, 0.330 mmol) , And dissolved in toluene (1.1 mL) under an argon atmosphere. To the reaction solution was added 2,5-dimethylpiperazine-1-carboxylic acid (2S, 5R) -tert-butyl (47 mg, 0.220 mmol), Pd 2 (dba) 3 (8.0 mg, 8.79 mumol), (±) -BINAP (11 mg, 0.0176 mmol) and potassium tert-butoxide (89 mg, 0.923 mmol) were sequentially added thereto, followed by stirring at 60 C. for 13 hours. After the completion of the reaction was confirmed, the reaction solution was concentrated under reduced pressure, and the obtained residue was purified using silica gel column chromatography (hexane / ethyl acetate) to obtain the title compound 48.7 mg (yield 38%) as a pale yellow oil It was obtained as a thing.

Reference： [1]Patent: JP2015/48326,2015,A .Location in patent: Paragraph 0108; 0126

42
N-[(R)-1-[(S)-1-hydroxypropan-2-yl]amino}propan-2-yl]-2-nitrobenzene sulfonamide [ No CAS ]
[ 548762-66-9 ]

Reference： [1]Patent: JP2015/48326,2015,A

43
tert-butyl [(S)-1-hydroxypropan-2-yl][(R)-2-(2-nitrophenylsulfonamido)propyl]carbamate [ No CAS ]
[ 548762-66-9 ]

Reference： [1]Patent: JP2015/48326,2015,A

44
[ 98-59-9 ]
[ 548762-66-9 ]
tert-butyl 3,3-dimethyl-4-[(4-methylphenyl)sulfonyl]piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In 1,2-dichloro-ethane; at 20℃;	To a stirred solution of 64 mg (0.3 mmol) tert-butyl (25,5R)-2,5-dimethylpiperazine-1- carboxylate in 2 mL DOE were added at RT 160 pL DIPEA (0.9 mmol, 3 eq) and 86 mg 4-methylbenzenesulfonyl chloride (0.45 mmol, 1.5 eq) and the mixture was stirred overnight at RT. The organic phase was washed three times with water, dried andevaporated to yield 110 mg (100%) of the crude title compound which was used in the next step without further purification.[C-MS (Method 1): Rt = 1.39 mm; MS (ESIpos): m/z = 369 [M÷H]

Reference： [1]Patent: WO2018/114672,2018,A1 .Location in patent: Page/Page column 53

45
3H-[1,2,3]triazole-4-carboxylic acid [ No CAS ]
[ 98-59-9 ]
[ 548762-66-9 ]
{(2S,5R)-2,5-dimethyl-4-[(4-methylphenyl)sulfonyl]piperazin-1-yl}(1H-1,2,3-triazol-5-yl)methanone [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
36%		To a solution of tert-butyl (25,5R)-2,5-dimethylpiperazine-i -carboxylate (0.3 mmol, 750 p[, 0.4 M) in DCE were added 4-methylbenzenesulfonyl chloride (0.45 mmol, 900 p[, 0.5M, 1 .5 eq) in DCE and 0.9 mmol DIPEA (156 p[, 3 eq) and the mixture was shakenovernight at RT. 2 m[ TFA/DCE 3:1 were added and the mixture was shaken at RT for3 h. After evaporation of the solvent, 1 H-i ,2,3-triazole-5-carboxylic acid (0.6 mmol, 1 .2 m[, 2 eq, 0.5M) in NMP, 928 p[ DIPEA (3.6 mmol, 12 eq; adjustment of pH to 8) and HATU (0.6 mmol, 1 .2 m[, 2 eq, 0.5 M) in NMP were added and the mixture was shaken overnight to yield after preparative HP[C 40 mg (36%) of the title compound.[C-MS (Method 2): Rt = 0.99 mm; MS (ESIpos): m/z = 364 [M÷H]

Reference： [1]Patent: WO2018/114672,2018,A1 .Location in patent: Page/Page column 55

46
[ 548762-66-9 ]
(2R,5S)-2,5-dimethyl-1-(phenylsulfonyl)piperazine [ No CAS ]

Reference： [1]Patent: WO2018/114670,2018,A1

47
[ 548762-66-9 ]
[(2S,5R)-2,5-dimethyl-4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-5-yl)methanone [ No CAS ]

Reference： [1]Patent: WO2018/114670,2018,A1

48
[ 98-09-9 ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-2,5-dimethyl-4-(phenylsulfonyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In tetrahydrofuran; at 20℃; for 72h;	To a stirred solution of 214 mg (1 mmol) tert-butyl (2S,5R)-2,5-dimethylpiperazine-1 - carboxylatein 3.3ml THF were added at RT 1.74 mL DIPEA (10 mmol, 10 eq) and 176 mg benzenesulfonyl chloride (1 mmol, 1 eq) and the mixture was stirred for 3 days at RT. The mixture was evaporated to yield 440 mg (124%) of the crude title compound which was used in the next step without further purification. LC-MS (Method 1 ): Rt = 1 .30 min; MS (ESIpos): m/z = 355 [M+H]+ (0524) 1H-NMR (500 MHz, DMSO-d6) delta [ppm]: 0.81 (3H), 0.99 (3H), 1 .37 (9H), 3.08 - 3.19 (3H), 3.51 - 3.67 (3H), 4.00 - 4.34 (2H), 7.62 (2H), 7.69 (1 H), 7.79 (2H).

Reference： [1]Patent: WO2018/114670,2018,A1 .Location in patent: Page/Page column 55; 56

49
3H-[1,2,3]triazole-4-carboxylic acid [ No CAS ]
[ 98-09-9 ]
[ 548762-66-9 ]
[(2S,5R)-2,5-dimethyl-4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-5-yl)methanone [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
29%		To a solution of tert-butyl (2S,5R)-2,5-dimethylpiperazine-1 -carboxylate (0.3 mmol, 750 muIota_, 0.4 M) in DCE were added benzenesulfonyl chloride (0.45 mmol, 900 muIota_, 0.5M, 1 .5 eq) in DCE and 0.9 mmol DIPEA (156 muIota_, 3 eq) and the mixture was shaken overnight at RT. 2 mL TFA DCE 3:1 were added and the mixture was shaken at RT for 3 h. After evaporation of the solvent, 1 H-1 ,2,3-triazole-5-carboxylic acid (0.6 mmol, 1 .2 mL, 2 eq, 0.5M) in NMP, 928 mu DIPEA (3.6 mmol, 12 eq; adjustment of pH to 8) and HATU (0.6 mmol, 1 .2 mL, 2 eq, 0.5 M) in NMP were added and the mixture was shaken overnight to yield after preparative HPLC 30 mg (29%) of the title compound.

Reference： [1]Patent: WO2018/114670,2018,A1 .Location in patent: Page/Page column 73

50
[ 701-27-9 ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-2,5-dimethyl-4-(3-fluorophenylsulfonyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In tetrahydrofuran; at 20℃; for 72h;	To a stirred solution of 214 mg (1 mmol) tert-butyl (2S,5R)-2,5-dimethylpiperazine-1- carboxylate in 3.3 mL THF were added at RT 1.74 mL DIPEA (10 mmol, 10 eq) and 194 mg 3- fluorobenzenesulfonyl chloride (1 mmol, 1 eq) and the mixture was stirred for 3 days at RT. The mixture was evaporated to yield 496 mg (133%) of the crude title compound which was used in the next step without further purification. (0532) LC-MS (Method 1): Rt = 1.33 min; MS (ESIpos): m/z = 373 [M+H]+ (0533) 1H-NMR (500 MHz, DMSO-d6) delta [ppm]: 0.84 (3H), 0.99 (3H), 1.38 (9H), 3.09 - 3.19 (3H), 3.54 - 3.67 (3H), 4.03 - 4.31 (2H), 7.56 (1 H), 7.61 - 7.72 (3H).

Reference： [1]Patent: WO2018/114670,2018,A1 .Location in patent: Page/Page column 56; 57

51
[ 701-27-9 ]
[ 548762-66-9 ]
(2R,5S)-1-[(3-fluorophenyl)sulfonyl]-2,5-dimethylpiperazine [ No CAS ]

Reference： [1]Patent: WO2018/114670,2018,A1

52
[ 210532-25-5 ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-[(3,5-difluorophenyl)sulfonyl]-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃;	To a stirred solution of 8.736 g (40.76 mmol) tert-butyl (2S,5R)-2,5-dimethylpiperazine-1 - carboxylate in 30 mL DCM were added at RT 21 .30 mL DIPEA (122.29 mmol, 3 eq) and 13 g 3-fluorobenzenesulfonyl chloride (61.15 mmol, 1 .5 eq) and the mixture was stirred overnight at RT. The organic phase was washed three times with water, dried and evaporated to yield 15.91 g (100%) of the crude title compound which was used in the next step without further purification. (0544) LC-MS (Method 1 ): Rt = 1.37 min; MS (ESIpos): m/z = 391 [M+H]+ (0545) 1H-NMR (400 MHz, DMSO-d6) delta [ppm]: 0.870 (2.76), 0.978 (2.40), 1 .374 (16.00), 2.518 (0.96), 2.523 (0.65), 3.176 (0.83), 3.207 (0.88), 3.360 (2.07), 3.391 (1 .29), 3.581 (0.47), 4.101 (0.61 ), 7.548 (2.26), 7.553 (3.33), 7.556 (2.41 ), 7.565 (2.95), 7.570 (2.61 ), 7.641 (0.55), 7.647 (1.00), 7.653 (0.57), 7.664 (1.16), 7.670 (1 .98), 7.676 (1 .05), 7.687 (0.57), 7.693 (0.96), 7.699 (0.50).

Reference： [1]Patent: WO2018/114670,2018,A1 .Location in patent: Page/Page column 58

53
[ 814-68-6 ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-acryloyl-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine; In dichloromethane; at 0℃; for 0.0833333h;	To a solution of <strong>[548762-66-9](2S,5R)-1-Boc-2,5-dimethylpiperazine</strong> (3.5 g, 16.33 mmol, AstaTech, Inc. Bristol, Pa., USA) and triethylamine (4.59 ml, 32.7 mmol) in DCM (35 mL) at 0 C. was added acryloyl chloride (1.46 ml, 17.96 mmol) over 5 min. Water (10 ml) was added and the mixture was warmed to rt and stirred for 10 min. The organic phase was collected, washed sequentially with 2.0 N HCl (40 ml), water, and brine. The reaction mixture was dried over MgSO4 and concentrated in vacuo to afford crude tert-butyl (2S,5R)-4-acryloyl-2,5-dimethylpiperazine-1-carboxylate (4.4 g, 16.4 mmol, 100% yield) as yellow oil. m/z (ESI, +ve ion): 213.3 (M-tBu+H)+.
	With triethylamine; In dichloromethane; at 0℃; for 0.0833333h;	To a solution of<strong>[548762-66-9](2S,5R)-1-Boc-2,5-dimethylpiperazine</strong> (3.5 g, 16.3 mmol, Astatech) in dichloromethane (35 ml), anhydrous triethylamine (4.59 ml, 32.7 mmol) was added and the mixture was cooled to 0 C. in ice-water bath. Acryloyl chloride (1.46 ml, 18.0 mmol) was added dropwise over ?5 min at which point the reaction mixture became yellow and viscous and formation of a white precipitate was observed. Water (10 ml) was added and the mixture was removed from the ice bath and was allowed to stir for 10 min. The organic layer was separated, quickly washed with 2N HCl (40 ml), water and brine, filtered through pad of MgSO4 and concentrated to afford crude tert-butyl (2S,5R)-4-acryloyl-2,5-dimethylpiperazine-1-carboxylate (4.4 g) as yellow oil. This material was redissolved in DCM (40 ml) and TFA (12.6 ml, 163 mmol) was added and the mixture was stirred at rt for 4 h at which point complete deprotection was observed. The mixture was concentrated under reduced pressure and dried under vacuum to afford 1-((2R,5S)-2,5-dimethylpiperazin-1-yl)prop-2-en-1-one 2,2,2-trifluoroacetate (Intermediate 160, ?9 g) as an oil.

Reference： [1]Patent: US2019/345169,2019,A1 .Location in patent: Paragraph 0275; 0276
[2]Patent: US2019/374542,2019,A1 .Location in patent: Paragraph 0834-0835

54
[ 548762-66-9 ]
1-((2R,5S)-4-(6-chloro-1-(6-((dimethylamino)methyl)-2-isopropyl-4-methylpyridin-3-yl)-7-(2-fluorophenyl)-2,2-dioxido-1H-pyrido[2,3-c][1,2,6]thiadiazin-4-yl)-2,5-dimethylpiperazin-1-yl)prop-2-en-1-one [ No CAS ]

Reference： [1]Patent: US2019/345169,2019,A1

55
[ 548762-66-9 ]
1-((2R,5S)-2,5-dimethylpiperazin-1-yl)prop-2-en-1-one 2,2,2-trifluoroacetate [ No CAS ]

Reference： [1]Patent: US2019/345169,2019,A1
[2]Patent: US2019/374542,2019,A1

56
[ 71783-54-5 ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(1-(4-fluorophenyl)-2-methoxy-2-oxoethyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
88%	With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 85℃; for 16h;	To a stirred solution of <strong>[548762-66-9]tert-butyl (2S,5R)-2,5-dimethylpiperazine-1-carboxylate</strong> (1.5 g, 7. mmol) in acetonitrile (15 mL) was added DIPEA (3.7 mL, 21 mmol) and methyl 2-bromo-2-(4-fluorophenyl)acetate (1.9 g, 7.7 mmol). The reaction mixture was heated up to 85 C over 10 min and was stirred for 16 h. The reaction mixture was concentrated under reduced pressure to obtain a brown gummy solid. The crude compound was purified by flash chromatography (using 24 g silica gel column; using 5 % -10 % ethylacetate/ Pet. ether) to obtain tert-butyl (2S,5R)-4-(1-(4-fluorophenyl)-2-methoxy-2- oxoethyl)-2,5-dimethylpiperazine-1-carboxylate (2.35 g, 6.18 mmol, 88% yield) as brown solid. LCMS: m/z, 379.3 (M-H); rt 1.13 min; Column: Waters Acquity UPLC BEH C18 (2.1 x 50 mm) 1.7 mm, Mobile phase A: 10 mM ammonium acetate:acetonitrile (95:5); Mobile phase B: 10 mM ammonium acetate:acetonitrile (5:95), Gradient = 20-90 % B over 1.1 minute, then a 0.6 minute hold at 90 % B; Temperature: 50 C; Flow rate: 0.7 mL/min; Detection: UV at 220 nm.

Reference： [1]Patent: WO2020/6018,2020,A1 .Location in patent: Page/Page column 779

57
methyl 2-bromo-2-(5-(trifluoromethyl)pyridin-2-yl)acetate [ No CAS ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(2-methoxy-2-oxo-1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
74%	With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 85℃; for 16h;	To a stirred solution of <strong>[548762-66-9]tert-butyl (2S,5R)-2,5-dimethylpiperazine-1-carboxylate</strong> (0.35 g, 1.63 mmol) in acetonitrile (8 mL) were added DIPEA (0.9 mL, 4.9 mmol) and methyl 2-bromo-2-(5-(trifluoromethyl)pyridin-2-yl)acetate (0.54 g, 1.79 mmol) at room temperature. The reaction mixture was heated at 85 C for 16 h. The reaction mixture was cooled to room temperature, concentrated under reduced pressure to obtain the crude product, which was purified by silica gel chromatography (24 g; using 6 % -10 % ethyl acetate/ petroleum ether) to obtain tert-butyl (2S,5R)-4-(2-methoxy-2-oxo-1-(5- (trifluoromethyl)pyridin-2-yl)ethyl)-2,5-dimethylpiperazine-1-carboxylate (0.52 g, 74 % yield). LCMS: m/z = 432.2 (M+H); retention time 2.19 min [LCMS method: Column: Waters Acquity UPLC BEH C18 (2.1 x 50 mm), 1.7 mm; Mobile phase A: 0.1% TFA in water; Mobile phase B: 0.1 % TFA in acetonitrile; Gradient = 20-90 % B over 1.1 minute, then a 0.6 minute hold at 90 % B; Temperature: 50 C; Flow rate: 0.7 mL/min; Detection: UV at 220 nm].

Reference： [1]Patent: WO2020/6018,2020,A1 .Location in patent: Page/Page column 810; 811

58
1-bromo-2-(bromo(4-fluorophenyl)methyl)benzene [ No CAS ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-((2-bromophenyl)(4-fluorophenyl)methyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
40%	With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 85℃; for 24h;	To a solution of <strong>[548762-66-9]tert-butyl (2S,5R)-2,5-dimethylpiperazine-1-carboxylate</strong> (500 mg, 2.33 mmol) in dry acetonitrile (3.0 mL), were added 1-bromo-2-(bromo(4- fluorophenyl)methyl)benzene (883 mg, 2.57 mmol) and DIPEA (1.22 mL, 7.0 mmol) at room temperature. The reaction mixture was heated at 85 C for 24 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by Combi flash 12 g silica gel (2632) chromatography by using 0-100% ethyl acetate/petroleum ether as eluent to obtain tert- butyl (2S,5R)-4-((2-bromophenyl)(4-fluorophenyl)methyl)-2,5-dimethylpiperazine-1- carboxylate (0.45 g, 40 % yield). 1H NMR (300 MHz, CDCl3) d ppm 7.75-7.89 (m, 1H), 7.25-7.60 (m, 4H), 6.91-7.17 (m, 3H), 5.02 (d, J=9.6 Hz, 1H), 4.12 (m, 1H), 3.51-3.72 (m, 1H), 3.30 (m, 1H), 2.93 (m, 1H), 2.57-2.71 (m, 1H), 2.17-2.31 (m, 1H), 1.37-1.65 (m, 9H), 1.14-1.33 (m, 3H), 0.82-1.05 (m, 3H).

Reference： [1]Patent: WO2020/6018,2020,A1 .Location in patent: Page/Page column 820; 821

59
[ 5445-17-0 ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(1-methoxy-1-oxopropan-2-yl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
88%	With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 85℃; for 16h;	To a stirred solution of <strong>[548762-66-9]tert-butyl (2S,5R)-2,5-dimethylpiperazine-1-carboxylate</strong> (500 mg, 2.33 mmol) in dry acetonitrile (10 mL), methyl 2-bromopropanoate (468 mg, 2.80 mmol) and DIPEA (1.22 mL, 7.00 mmol) were added at room temperature. The reaction mixture was heated to 85 C for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by Combi flash 24 g silica gel chromatography by using 0-30% ethyl acetate in petroleum ether as eluent to obtain tert-butyl (2S,5R)-4-(1-methoxy-1-oxopropan-2- yl)-2,5-dimethylpiperazine-1-carboxylate (620 mg, 88 % yield) as a light yellow liquid. LCMS: m/z, 301.2 (M+H); retention time 2.941 and 3.094 min. Column: Kinetex XB- C18 (3 x 75 mm) 2.6 mm; Mobile phase A: 10 mM ammonium formate: acetonitrile (98:2), Mobile phase B: 10 mM ammonium formate: acetonitrile (2:98), Gradient = 20- 100 % B over 4 minutes, then a 0.6 minute hold at 100 % B; Temperature: 27 C; Flow rate: 1.0 mL/min; Detection: UV at 220 nm

Reference： [1]Patent: WO2020/6018,2020,A1 .Location in patent: Page/Page column 836; 837

60
1-bromo-4-(1-bromoethyl)-2-fluorobenzene [ No CAS ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(1-(4-bromo-3-fluorophenyl)ethyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
27%	With sodium hydrogencarbonate; In acetonitrile; at 80℃; for 12h;	To a stirred solution of <strong>[548762-66-9]tert-butyl (2S,5R)-2,5-dimethylpiperazine-1-carboxylate</strong> (0.5 g, 2.33 mmol) in acetonitrile (10 mL) were added sodium bicarbonate (0.98 g, 11.67 mmol) and 1-bromo-4-(1-bromoethyl)-2-fluorobenzene (0.66 g, 2.33 mmol) at room temperature. The reaction mixture was heated at 80 C for 12 h. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure to obtain the crude product, which was purified by flash column chromatography (Column: 24 g silica; Solvent run: 40-45% EtOAc in petroleum ether) to obtain a diastereomeric mixture of tert-butyl (2S,5R)-4-(1-(4-bromo-3-fluorophenyl)ethyl)-2,5- dimethylpiperazine-1-carboxylate (0.3 g, 27 % yield) as an off-white solid. LCMS: m/z, 416.2 (M+2); retention time 3.55 min. (LC-MS Method info: Column-KINETEX- XB- C18 (75 x 3 mm- 2.6 ^m ); Mphase A: 10 mM ammonium formate in water: acetonitrile (98:2); Mphase B: 10 mM ammonium formate in water: acetonitrile (2:98); Gradient: 20- 100% B over 4 minutes, flow rate 1.0 mL/min, then a 0.6 minute hold at 100% B flow rate 1.5 mL/min; then Gradient: 100-20% B over 0.1 minutes, flow rate 1.5 mL/min).

Reference： [1]Patent: WO2020/6018,2020,A1 .Location in patent: Page/Page column 856; 857

61
[ 50793-48-1 ]
[ 548762-66-9 ]
dimethyl 4,4'-(((2R,5S)-4-(tert-butoxycarbonyl)-2,5-dimethylpiperazin-1-yl)methylene)dibenzoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
30.2%	With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 85℃; for 16h;	To a stirred solution of <strong>[548762-66-9]tert-butyl (2S,5R)-2,5-dimethylpiperazine-1-carboxylate</strong> (0.2 g, 0.93 mmol) in acetonitrile (6 mL) were added DIPEA (0.5 mL, 2.80 mmol) and dimethyl 4,4'-(bromomethylene)dibenzoate (0.373 g, 1.03 mmol) at room temperature. The reaction mixture was heated at 85 C for 16 h. The volatiles were removed from the reaction mixture under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (24 g, 12 %-17 % ethyl acetate/ petroleum ether) to obtain dimethyl 4,4'-(((2R,5S)-4-(tert-butoxycarbonyl)-2,5-dimethylpiperazin-1-yl) methylene)dibenzoate (140 mg, 30.2 % yield). LCMS: m/z = 497.2 (M+H); retention time 2.52 min [LCMS method: Column: Waters Acquity UPLC BEH C18 (2.1 x 50 mm) 1.7 mm, Mobile phase A: 10 mM NH4OAc: acetonitrile (95:5); Mobile phase B: 10 mM NH4OAc:acetonitrile (5:95), Gradient = 20-90 % B over 1.1 minute, then a 0.6 minute hold at 90 % B; Temperature: 50 C; Flow rate: 0.7 mL/min; Detection: UV at 220 nm].

Reference： [1]Patent: WO2020/6018,2020,A1 .Location in patent: Page/Page column 875; 876

62
[ 403-43-0 ]
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(4-fluorobenzoyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
83%	With N-ethyl-N,N-diisopropylamine; HATU; In acetonitrile; at 20℃;	To a stirred solution of 4-fluorobenzoyl chloride(1.0 g, 7.14 mmol) in acetonitrile (10 mL) were added DIPEA (3.74 mL, 21.41 mmol) and HATU (3.53 g, 9.28 mmol) at room temperature. After 30 min., tert-butyl (2S,5R)-2,5-dimethylpiperazine-1- carboxylate (1.83 g, 8.56 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure to remove volatiles and the residue dissolved in ethyl acetate (100 mL) and washed with water (50 mL). The aqueous layer was back extracted with ethyl acetate (100 mL x 2) and the combined organic layer was washed with brine, dried over anhydrous Na2SO4, concentrated under reduced pressure to obtain the crude product, which was purified by silica gel chromatography (50-100% EtOAc in petroleum ether; 40 g column) to afford tert-butyl (2S,5R)-4-(4-fluorobenzoyl)-2,5-dimethylpiperazine-1-carboxylate (1.99 g, 83 % yield). LCMS: m/z = 337.1 (M+H); retention time 1.62 min. [LCMS Condition: Column: Waters Acquity UPLC BEH C18 (2.1 x 50 mm) 1.7 mm, Mobile phase A: 10 mM NH4OAc:acetonitrile (95:5); Mobile phase B: 10 mM NH4OAc:acetonitrile (5:95), Gradient = 20-90 % B over 1.1 minute, then a 0.6 minute hold at 90 % B; Temperature: 50 C; Flow rate: 0.7 mL/min; Detection: UV at 220 nm].

Reference： [1]Patent: WO2020/6018,2020,A1 .Location in patent: Page/Page column 936

63
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(1-(4-fluorophenyl)-2-hydroxyethyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

64
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(2-hydroxy-1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

65
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(2-methoxy-1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

66
[ 548762-66-9 ]
(2R,5S)-1-(2-methoxy-1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-2,5-dimethylpiperazine trifluoroacetate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

67
[ 548762-66-9 ]
8-((2S,5R)-4-((1S)-2-methoxy-1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]
8-((2S,5R)-4-((1R)-2-methoxy-1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

68
[ 548762-66-9 ]
((2R,5S)-2,5-dimethylpiperazin-1-yl)-2-(5-(trifluoromethyl)pyridin-2-yl)ethan-1-ol [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

69
[ 548762-66-9 ]
8-((2S,5R)-4-((1S)-2-hydroxy-1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]
8-((2S,5R)-4-((1R)-2-hydroxy-1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

70
[ 548762-66-9 ]
2-((2R,5S)-4-(tert-butoxycarbonyl)-2,5-dimethylpiperazin-1-yl)propanoic acid patasssium salt [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

71
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(1-(4-fluorophenyl)-2-hydroxy-2-methylpropyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

72
[ 548762-66-9 ]
1-((2R,5S)-2,5-dimethylpiperazin-1-yl)-1-(4-fluorophenyl)-2-methylpropan-2-ol trifluoroacetate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

73
[ 548762-66-9 ]
8-((2S,5R)-4-((1R)-1-(4-fluorophenyl)-2-hydroxy-2-methylpropyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]
8-((2S,5R)-4-((1S)-1-(4-fluorophenyl)-2-hydroxy-2-methylpropyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

74
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(3-ethoxy-2,2-difluoro-1-(4-fluorophenyl)-3-oxopropyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1
[2]Patent: WO2020/6018,2020,A1

75
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(2,2-difluoro-1-(4-fluorophenyl)-3-hydroxypropyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1
[2]Patent: WO2020/6018,2020,A1

76
[ 548762-66-9 ]
3-((2R,5S)-2,5-dimethylpiperazin-1-yl)-2,2-difluoro-3-(4-fluorophenyl)propan-1-ol trifluoroacetate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1
[2]Patent: WO2020/6018,2020,A1

77
[ 548762-66-9 ]
8-((2S,5R)-4-((1R)-2,2-difluoro-1-(4-fluorophenyl)-3-hydroxypropyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]
8-((2S,5R)-4-((1S)-2,2-difluoro-1-(4-fluorophenyl)-3-hydroxypropyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1
[2]Patent: WO2020/6018,2020,A1

78
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(2,2-difluoro-1-(4-fluorophenyl)-3-methoxypropyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1
[2]Patent: WO2020/6018,2020,A1

79
[ 548762-66-9 ]
(2R,5S)-1-(2,2-difluoro-1-(4-fluorophenyl)-3-methoxypropyl)-2,5-dimethylpiperazine trifluoroacetate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1
[2]Patent: WO2020/6018,2020,A1

80
[ 548762-66-9 ]
8-((2S,5R)-4-((1R)-2,2-difluoro-1-(4-fluorophenyl)-3-methoxypropyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]
8-((2S,5R)-4-((1S)-2,2-difluoro-1-(4-fluorophenyl)-3-methoxypropyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1
[2]Patent: WO2020/6018,2020,A1

81
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(bis(4-(hydroxymethyl)phenyl)methyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

82
[ 548762-66-9 ]
((((2R,5S)-2,5-dimethylpiperazin-1-yl)methylene)bis(4,1-phenylene))dimethanol hydrochloride [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

83
[ 548762-66-9 ]
8-((2S,5R)-4-(bis(4-(hydroxymethyl)phenyl)methyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

84
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-(1-(4-fluorophenyl)cyclopropyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1
[2]Patent: WO2020/6018,2020,A1

85
[ 548762-66-9 ]
(2S,5R)-4-(1-(4-fluorophenyl)cyclopropyl)-2,5-dimethylpiperazin-1-ium chloride [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1
[2]Patent: WO2020/6018,2020,A1

86
[ 548762-66-9 ]
8-((2S,5R)-4-(1-(4-fluorophenyl)cyclopropyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1
[2]Patent: WO2020/6018,2020,A1

87
[ 548762-66-9 ]
tert-butyl (2S,5R)-4-((3-cyclopropyl-1,2,4-oxadiazol-5-yl)(4-fluorophenyl)methyl)-2,5-dimethylpiperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

88
[ 548762-66-9 ]
3-cyclopropyl-5-(((2R,5S)-2,5-dimethylpiperazin-1-yl)(4-fluorophenyl)methyl)-1,2,4-oxadiazole trifluoroacetate [ No CAS ]

Reference： [1]Patent: WO2020/6018,2020,A1

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 548762-66-9 ]

Amides

[ 960283-58-3 ]

(S)-tert-Butyl 2-methylpiperazine-1-carboxylate hydrochloride

Similarity: 0.98

[ 1017606-58-4 ]

(S)-tert-Butyl 4-(2-aminopropyl)piperazine-1-carboxylate

Similarity: 0.98

[ 674792-07-5 ]

tert-Butyl 2,2-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 259808-67-8 ]

tert-Butyl 3,3-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 2061980-49-0 ]

tert-Butyl 3-(piperazin-1-yl)azetidine-1-carboxylate dihydrochloride

Similarity: 0.96

Related Parent Nucleus of
[ 548762-66-9 ]

Piperazines

[ 960283-58-3 ]

(S)-tert-Butyl 2-methylpiperazine-1-carboxylate hydrochloride

Similarity: 0.98

[ 1017606-58-4 ]

(S)-tert-Butyl 4-(2-aminopropyl)piperazine-1-carboxylate

Similarity: 0.98

[ 674792-07-5 ]

tert-Butyl 2,2-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 259808-67-8 ]

tert-Butyl 3,3-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 2061980-49-0 ]

tert-Butyl 3-(piperazin-1-yl)azetidine-1-carboxylate dihydrochloride

Similarity: 0.96

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 548762-66-9 ] {[proInfo.proName]}

Quality Control of [ 548762-66-9 ]

Related Doc. of [ 548762-66-9 ]

Product Details of [ 548762-66-9 ]

Calculated chemistry of [ 548762-66-9 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 548762-66-9 ]

Application In Synthesis of [ 548762-66-9 ]

[ 548762-66-9 ] Synthesis Path-Upstream 1~7

[ 548762-66-9 ] Synthesis Path-Downstream 1~88

Related Functional Groups of [ 548762-66-9 ]

Amides

Related Parent Nucleus of [ 548762-66-9 ]

Piperazines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 548762-66-9 ]

Related Parent Nucleus of
[ 548762-66-9 ]